drugset
drugset / Trial / NCT00958412

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

NCT00958412 ↗

Phase 2 Terminated 18 enrolled Repros Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

ZPE-201 Extension of treatment

Timeline

Start
2009-02-28
Primary completion
2009-08-31
Completion
2009-08-31

Outcome

Outcome not reported

Stopped: “Repros stopped the study for safety and FDA put the study on hold for safety.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Proellex Other / unclassified 25 mg —

Indications

endometriosis